Osmetech acquired the Opti product line from Roche Diagnostics. Opti is the portable analysis technology for bloodgas and electrolytes measurement. This highly successful analyser has also taken the veterinary world by storm. IDEXX Laboratories Inc (IDXX) have entered into a ten year OEM agreement to provide the customised OPTI analysers to the veterinary field under the brand VetStat.

In September 2004 the company acquired the "OPTIgene" (Genedrive) product from MS this technology will enable OMH a strong entry point into the fastest growing market segment of DNA based diagnostics. A market that is growing at an annual rate of 20% and is currently worth $ 22 bln !

In the latest acquisition 1/7/05 Osmetech acquired Clinical Micro Sensors from Motorola PLC, OMH plans to utilise the eSensor technology coupled with OPTIgene to address the majority of existing and new tests in the genetic diagnostics market. 'CMS's diagnostic tests for cystic fibrosis and CYP450 are closest to commercial launch and OMH believes that these products have significant market potential.

Scroll & Click for Websites & Other LinksRT Mag Wall Street Reporter Interviews JW

Up Coming Events in 2006

CMS CYP450 product Launch!!!!!............................................. 2006

IDEXX critical care platform Launch!!!!!....................................2006/7....much more to follow

Click Here to Track Osmetech's Progress in the "Stocks That Could Double in 2006" Competition

hobbst, what a clueless tosser

DITCHPIG

Good of you to let the world see what a great command you have of the english language.

hobbst, what a clueless tosser

Been reading all the personal abuse that both DITCHPIG and bangers(mam) get up to on ADVFN, while ramping OMH - their only shareholding. No wonder that people on that website are fed up with their antics and have even set up a thread to try and exclude people like these, in order to get a level debate.

Come on Money AM, must be time to get rid of these idiots from your bulletin boards.

What a spastic! Why should MoneyAM give a t0ss what happens on a rival website. LOL.

Come on Money AM, this poster is deliberately out to ruin a thread i've set up for research/info etc on OSMETECH.
As an HTML novice the header alone took me a week to sort out the coding.

The rival site gives the thread creator the option to ban idiots like hobbst from their own threads, this way all the hobbts's (gerry2's) can join force on one alternate thread and talk crap all day and leaving a serious (my) thread for investors.

Perhaps genuine users should be given this same 'moderate' option here?

Well, lets face it, not much serious debate happens on your thread as you spend most of the time abusing contributors !!!!!!!!!!

By the way, I am not gerry2 on ADVFN. Glad to see that he treats your abuse the same way as I do ........ yeh, whatever.

hobbst, what a clueless tosser

Osmetech go live with their new quality and customer management systems.

http://www.pilgrimsoftware.com/press/Pasadena-Go-Live-Pilgrim.shtml

and a presentation about the process. Read the slides so you can understand why it is necessary to use these tools.

http://www.advamed.org/publicdocs/pilgrim_study.pdf

Osmetech at the Deutschen Gesellschaft f Anthesiologie und Intensivmedizin (DGAI) wird vom 05. 08. May 2007 in Hamburg.

http://www.dac2007.de/aussteller/dac2007-aussteller-086.htm

..............looks like this is going to be a very lonely thread for DITCHPIG and bangersmam to ramp this dog of a share...... hope you are both very happy together.......bye bye

hobbst, what a clueless tosser

LOL

hobbst, what a clueless tosser

LOL

One of Moneyam;s thickest. A complete pratt.


hobbst - 10 Nov 2006 14:22 - 138 of 138 (squelched)

Price starting to creap back up after the recent profit taking. 30p seems a real possibility from the next leg of the breakout - Finbonacci projection also puts this area as the next price target.

Looking Good.

when the price has crept back to recent highs further good news from the company should propel it back to the 30-40p level. Given that we are expecting a strong results update In Januray the start of 2007 could be very interesting!

hobbst your totally correct in your observations.

Motoring today. Up 8% plenty more to come.
Lookng good

Incidentally the price hasn't stop motoring since the thread 'zits' popped up.

60% in 6 weeks will do for starters, with no fund raising needs (like last year) the resistance at mid 30p's should be a piece of cake.

RNS Number:0992M
Osmetech PLC
15 November 2006



Osmetech increases patent holdings November 15, 2006


Pasadena, California, USA - Osmetech Molecular Diagnostics (Osmetech), a fast
developing, international diagnostics business serving the high growth, near
patient molecular testing market, today announced that it has been granted a UK
patent covering its OPTI TUBETM plastic capillary product. The grant of the UK
patent follows the recent registration of a German Utility Model which also
covers Osmetech's innovative plastic vessel. The tube is made from cyclic olefin
and has excellent rigidity, optical and thermal properties making it the product
of choice for PCR thermal cycling and other applications that traditionally
employ breakable glass. Adding to this versatility and novelty, Osmetech also
sells a carousel housing for the OPTI TUBEs that fits the Roche Lightcycler(R).

The new patent, GB 2409659, is just one of a number of patents issued to
Osmetech in the last six months, according to Edward Kreusser, Osmetech's VP of
Intellectual Property and Legal Affairs. Osmetech now owns or holds exclusive
rights to some 130 patents worldwide (70 US) mostly in the field of
electrochemical detection for biological entities such as nucleic acids and
proteins which offers significant advantages over other methods.

Osmetech's growing patent estate boasts tens of millions in investment over the
last decade from Motorola, Caltech, Harvard University and the University of
North Carolina who continue to have a vested interest in the technology and are
pleased to see the great commercial potential of the portfolio become a reality.

This latest development builds on momentum achieved earlier this year when
Osmetech received FDA approval to launch its eSensor(R) electrochemistry-based
array system for cystic fibrosis carrier detection. In addition to other
projects, Osmetech plans to follow with a battery of related pharmacogenomic
CYP450 assays emploing the same electrochemical detection platform.

Contact Osmetech:

Edward Kreusser, Esq.